General Information of Drug Therapeutic Target (DTT) (ID: TTW0CMT)

DTT Name Voltage-gated potassium channel Kv1.5 (KCNA5)
Synonyms
Voltage-gatedpotassium channel subunit Kv1.5; Voltage-gated potassium channel subunit Kv1.5; Voltage-gated potassium channel HK2; Potassium voltage-gated channel subfamily A member 5; Potassium channel Kv1.5; HPCN1; HK2; 02-Sensitive Potassium Channel Kv1.5
Gene Name KCNA5
DTT Type
Successful target
[1]
BioChemical Class
Voltage-gated ion channel
UniProt ID
KCNA5_HUMAN
TTD ID
T17569
3D Structure
Download
2D Sequence (FASTA)
Download
3D Structure (PDB)
Download
Sequence
MEIALVPLENGGAMTVRGGDEARAGCGQATGGELQCPPTAGLSDGPKEPAPKGRGAQRDA
DSGVRPLPPLPDPGVRPLPPLPEELPRPRRPPPEDEEEEGDPGLGTVEDQALGTASLHHQ
RVHINISGLRFETQLGTLAQFPNTLLGDPAKRLRYFDPLRNEYFFDRNRPSFDGILYYYQ
SGGRLRRPVNVSLDVFADEIRFYQLGDEAMERFREDEGFIKEEEKPLPRNEFQRQVWLIF
EYPESSGSARAIAIVSVLVILISIITFCLETLPEFRDERELLRHPPAPHQPPAPAPGANG
SGVMAPPSGPTVAPLLPRTLADPFFIVETTCVIWFTFELLVRFFACPSKAGFSRNIMNII
DVVAIFPYFITLGTELAEQQPGGGGGGQNGQQAMSLAILRVIRLVRVFRIFKLSRHSKGL
QILGKTLQASMRELGLLIFFLFIGVILFSSAVYFAEADNQGTHFSSIPDAFWWAVVTMTT
VGYGDMRPITVGGKIVGSLCAIAGVLTIALPVPVIVSNFNYFYHRETDHEEPAVLKEEQG
TQSQGPGLDRGVQRKVSGSRGSFCKAGGTLENADSARRGSCPLEKCNVKAKSNVDLRRSL
YALCLDTSRETDL
Function
Forms tetrameric potassium-selective channels through which potassium ions pass in accordance with their electrochemical gradient. The channel alternates between opened and closed conformations in response to the voltage difference across the membrane. Can form functional homotetrameric channels and heterotetrameric channels that contain variable proportions of KCNA1, KCNA2, KCNA4, KCNA5, and possibly other family members as well; channel properties depend on the type of alpha subunits that are part of the channel. Channel properties are modulated by cytoplasmic beta subunits that regulate the subcellular location of the alpha subunits and promote rapid inactivation. Homotetrameric channels display rapid activation and slow inactivation. May play a role in regulating the secretion of insulin in normal pancreatic islets. Isoform 2 exhibits a voltage-dependent recovery from inactivation and an excessive cumulative inactivation. Voltage-gated potassium channel that mediates transmembrane potassium transport in excitable membranes.
Reactome Pathway
Voltage gated Potassium channels (R-HSA-1296072 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA) Jump to Detail Molecular Interaction Atlas of This DTT
1 Approved Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Dronedarone DMA8FS5 Angina pectoris BA40 Approved [1]
------------------------------------------------------------------------------------
5 Clinical Trial Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
BMS-919373 DMN28WK Atrial fibrillation BC81.3 Phase 2 [2]
BMS-394136 DMGDJQR Arrhythmia BC9Z Phase 1 [3]
IQB-9302 DMET0H4 Pain MG30-MG3Z Phase 1 [4]
XEN-D0101 DMU0V45 Atrial fibrillation BC81.3 Phase 1 [5]
XEN-D0103 DMR0U4V Atrial fibrillation BC81.3 Phase 1 [6]
------------------------------------------------------------------------------------
1 Preclinical Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
T-226296 DMJ6P9U Obesity 5B81 Preclinical [1]
------------------------------------------------------------------------------------
1 Discontinued Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
Zatebradine DMNYKOT Angina pectoris BA40 Terminated [7]
------------------------------------------------------------------------------------
20 Investigative Drug(s) Targeting This DTT
Drug Name Drug ID Indication ICD 11 Highest Status REF
2-amino-2-phenyl-1,1-di(pyridin-3-yl)ethanol DM14HCY Discovery agent N.A. Investigative [8]
2-morpholino-1,1,2-triphenylethanol DMFHTEG Discovery agent N.A. Investigative [8]
2-morpholino-1,1-di(pyridin-3-yl)hexan-1-ol DMH89O5 Discovery agent N.A. Investigative [8]
2-morpholino-1,1-di(pyridin-3-yl)octan-1-ol DMDMVA1 Discovery agent N.A. Investigative [8]
2-morpholino-2-phenyl-1,1-di(pyridin-3-yl)ethanol DM3V5AB Discovery agent N.A. Investigative [8]
2-phenoxy-1-(2-p-tolylthiazolidin-3-yl)ethanone DMQX7FW Discovery agent N.A. Investigative [9]
2-phenyl-1,1-di(pyridin-3-yl)ethanol DMERNSK Discovery agent N.A. Investigative [8]
3-(4-methoxybenzyloxy)-2-phenylthiazolidin-4-one DMFRZGS Discovery agent N.A. Investigative [9]
3-(benzyloxy)-2-(4-chlorophenyl)thiazolidin-4-one DMD4WHN Discovery agent N.A. Investigative [9]
3-methyl-2-morpholino-1,1-diphenylbutan-1-ol DMKWAV6 Discovery agent N.A. Investigative [8]
4-(4-phenoxybutoxy)-7H-furo[3,2-g]chromen-7-one DMKMH5L Discovery agent N.A. Investigative [10]
clofilium DMQ37OP Discovery agent N.A. Investigative [11]
DPO-1 DMHCZP0 Atrial fibrillation BC81.3 Investigative [6]
N-Benzyl-2-(toluene-4-sulfonylamino)-benzamide DM3C0P2 Discovery agent N.A. Investigative [12]
N-Phenethyl-2-(toluene-4-sulfonylamino)-benzamide DM1BU5P Discovery agent N.A. Investigative [12]
NIP-142 DMV53PH Atrial fibrillation BC81.3 Investigative [1]
RS-100302 DM63NGW Atrial fibrillation BC81.3 Investigative [1]
S-9947 DMHB6UY Atrial fibrillation BC81.3 Investigative [1]
XEN-D0104 DM1EHG5 Atrial fibrillation BC81.3 Investigative [6]
[14C]TEA DM6SFYH Discovery agent N.A. Investigative [13]
------------------------------------------------------------------------------------
⏷ Show the Full List of 20 Investigative Drug(s)

The Drug Transporter (DTP) Role of This DTT

DTT DTP Name Voltage-gated potassium channel subunit Kv1.5 (KCNA5) DTP Info
Gene Name KCNA5

References

1 New antiarrhythmic agents for atrial fibrillation and atrial flutter. Expert Opin Emerg Drugs. 2005 May;10(2):311-22.
2 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800035504)
3 Interpreting expression profiles of cancers by genome-wide survey of breadth of expression in normal tissues. Genomics 2005 Aug;86(2):127-41.
4 Stereoselective effects of the enantiomers of a new local anaesthetic, IQB-9302, on a human cardiac potassium channel (Kv1.5). Br J Pharmacol. 2001 Jan;132(2):385-92.
5 Human electrophysiological and pharmacological properties of XEN-D0101: a novel atrial-selective Kv1.5/IKur inhibitor. J Cardiovasc Pharmacol. 2013 May;61(5):408-15.
6 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 542).
7 DOI: 10.1161/01.CIR.94.3.562
8 Discovery of triarylethanolamine inhibitors of the Kv1.5 potassium channel. Bioorg Med Chem Lett. 2010 Apr 15;20(8):2493-6.
9 Evolution of thiazolidine-based blockers of human Kv1.5 for the treatment of atrial arrhythmias. Bioorg Med Chem Lett. 2007 Jan 1;17(1):282-4.
10 Substituted N-{3-[(1,1-dioxido-1,2-benzothiazol-3-yl)(phenyl)amino]propyl}benzamide analogs as potent Kv1.3 ion channel blockers. Part 2. Bioorg Med Chem Lett. 2010 Dec 1;20(23):6989-92.
11 Mechanism of clofilium block of the human Kv1.5 delayed rectifier potassium channel. Mol Pharmacol. 1995 Jan;47(1):198-205.
12 Pharmacophore-based search, synthesis, and biological evaluation of anthranilic amides as novel blockers of the Kv1.5 channel. Bioorg Med Chem Lett. 2004 Jun 7;14(11):2823-7.
13 Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines. Mol Pharmacol. 1994 Jun;45(6):1227-34.